Anaptysbio Inc (ANAB)

$65.93 -1.57 (-2.33%)
Market Cap 1.92B
Revenue (ttm) 234.60M
Net Income (ttm) -13.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.64%
Debt to Equity Ratio 0.00
Volume 259,639
Avg Vol 632,098
Day's Range N/A - N/A
Shares Out 29.10M
Stochastic %K 87%
Beta 0.72
Analysts Strong Sell
Price Target $87.09

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
thecontracap
thecontracap Jun. 18 at 8:29 PM
$ANAB anyone know the litigation with gsk in detail? Seems to me like $ANAB either gets a big royalty bump or they get acquired. Would like to compare notes in anyone involved.
1 · Reply
StockBraker
StockBraker Jun. 11 at 5:16 PM
$ANAB Should have sold more at $72. 😩
0 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 10 at 2:22 PM
$SPRO only to (1) avoid milestones/royalties to improve gross margin/operating earnings % and (2) avoid a future license dispute like $GSK and $ANAB and optimize GSK's $9 million equity investment in SPRO into something more useful via rolling into a reverse merge target.
0 · Reply
DARKP00L
DARKP00L Jun. 10 at 11:38 AM
$ANAB 06:20 on Jun. 10 2026 HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95 #tradeideas
0 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 9 at 4:21 PM
maybe the miscalculation re $SPRO all along is $GSK doesn't mind cutting milestone/royalty checks. Seems odd to me if you can extinguish those payments on what is supposedly a potential blockbuster. I thought GSK would want full control of all its blockbusters and out-license non-blockbusters like it did with Lynavoy in March 2026. GSK has problem with $ANAB and the jemperli license ...
1 · Reply
Reanimated666
Reanimated666 Jun. 3 at 11:20 AM
$ANAB After the spinoff the stock has dumped
1 · Reply
StockBraker
StockBraker May. 22 at 1:33 AM
$ANAB My friend would appreciate this part of this article. https://www.zacks.com/stock/news/2923367/wall-street-analysts-see-a-3875-upside-in-anaptysbio-anab-can-the-stock-really-move-this-high?cid=CS-STOCKTWITS-HL-tale_of_the_tape|consensus_price_target-2923367&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2923367#:~:text=Here%27s%20What%20You%20Should%20Know%20About%20Analysts%27%20Price%20Targets
1 · Reply
inelegantinvest
inelegantinvest May. 21 at 1:59 PM
$ANAB completed the First Tracks Biotherapeutics spinoff. Now ANAB is the royalty/cash story, while $TRAX.X is the pipeline company. The split makes the investment question cleaner — but not automatically cheaper. We looked at both sides: https://www.stockspinoffs.com/2026/05/21/anaptysbio-first-tracks-spinoff-completed/
0 · Reply
Grallen
Grallen May. 19 at 8:31 PM
$ANAB https://www.instagram.com/reel/DYfXmRshgf-/?igsh=MWNlaDQxZmwxZHUycQ==
0 · Reply
Grallen
Grallen May. 8 at 8:50 PM
$ANAB https://www.instagram.com/p/DX9EIjmMhfQ/?igsh=MTRweGgyNnJnOTU1MQ==
0 · Reply
Latest News on ANAB
AnaptysBio Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 2 days ago

AnaptysBio Proxy statement: Proxy filing

AnaptysBio Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 2 days ago

AnaptysBio Proxy statement: Proxy filing

AnaptysBio assumed with a Buy at H.C. Wainwright

2026-06-10T10:19:07.000Z - 21 days ago

AnaptysBio assumed with a Buy at H.C. Wainwright

AnaptysBio price target raised to $90 from $85 at Leerink

2026-05-15T16:45:33.000Z - 6 weeks ago

AnaptysBio price target raised to $90 from $85 at Leerink

GSK

AnaptysBio price target raised to $76 from $60 at UBS

2026-05-13T12:17:45.000Z - 7 weeks ago

AnaptysBio price target raised to $76 from $60 at UBS

AnaptysBio price target raised to $75 from $63 at Barclays

2026-05-13T09:01:49.000Z - 7 weeks ago

AnaptysBio price target raised to $75 from $63 at Barclays

AnaptysBio reports Q1 EPS ($1.84), consensus (75c)

2026-05-12T20:47:39.000Z - 7 weeks ago

AnaptysBio reports Q1 EPS ($1.84), consensus (75c)

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 4:15 PM EDT - 7 weeks ago

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

AnaptysBio Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 7 weeks ago

AnaptysBio Earnings release: Q1 2026

AnaptysBio Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 7 weeks ago

AnaptysBio Quarterly report: Q1 2026

AnaptysBio appoints Christopher Murphy as CFO

2026-05-11T20:06:02.000Z - 7 weeks ago

AnaptysBio appoints Christopher Murphy as CFO

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

May 11, 2026, 9:15 AM EDT - 7 weeks ago

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026, 4:15 PM EDT - 2 months ago

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

AnaptysBio price target lowered to $93 from $95 at Piper Sandler

2026-05-04T11:53:49.000Z - 2 months ago

AnaptysBio price target lowered to $93 from $95 at Piper Sandler

GSK TRAX VNDA

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Apr 28, 2026, 7:12 PM EDT - 2 months ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

VNDA

AnaptysBio price target raised to $85 from $66 at Leerink

2026-04-28T10:29:57.000Z - 2 months ago

AnaptysBio price target raised to $85 from $66 at Leerink

GSK’s TESARO provides update on AnaptysBio litigation

2026-04-27T10:41:58.000Z - 2 months ago

GSK’s TESARO provides update on AnaptysBio litigation

GSK

Delaware court dismisses Tesaro breach of contract claim against AnaptysBio

2026-04-24T19:50:20.000Z - 2 months ago

Delaware court dismisses Tesaro breach of contract claim against AnaptysBio

GSK

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

Apr 24, 2026, 3:40 PM EDT - 2 months ago

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

AnaptysBio price target lowered to $60 from $90 at UBS

2026-04-22T13:52:10.000Z - 2 months ago

AnaptysBio price target lowered to $60 from $90 at UBS

AnaptysBio price target lowered to $63 from $79 at Barclays

2026-04-22T09:36:10.000Z - 2 months ago

AnaptysBio price target lowered to $63 from $79 at Barclays

AnaptysBio price target lowered to $60 from $90 at UBS

2026-04-21T13:14:24.000Z - 2 months ago

AnaptysBio price target lowered to $60 from $90 at UBS

GSK VNDA

AnaptysBio completes separation of First Tracks Biotherapeutics

2026-04-20T15:31:29.000Z - 2 months ago

AnaptysBio completes separation of First Tracks Biotherapeutics

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Apr 20, 2026, 9:15 AM EDT - 2 months ago

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

AnaptysBio price target raised to $95 from $67 at Piper Sandler

2026-03-31T10:51:07.000Z - 3 months ago

AnaptysBio price target raised to $95 from $67 at Piper Sandler

AnaptysBio announces $100M share repurchase program

2026-03-27T13:13:30.000Z - 3 months ago

AnaptysBio announces $100M share repurchase program

AnaptysBio board approves spin-off of First Tracks Biotherapeutics

2026-03-27T13:06:05.000Z - 3 months ago

AnaptysBio board approves spin-off of First Tracks Biotherapeutics

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Mar 27, 2026, 9:00 AM EDT - 3 months ago

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Mar 27, 2026, 9:00 AM EDT - 3 months ago

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Mar 27, 2026, 9:00 AM EDT - 3 months ago

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

AnaptysBio price target raised to $90 from $70 at UBS

2026-03-17T10:45:14.000Z - 3 months ago

AnaptysBio price target raised to $90 from $70 at UBS

AnaptysBio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 2:20 PM EDT - 4 months ago

AnaptysBio Transcript: Leerink Global Healthcare Conference 2026

AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:30 AM EDT - 4 months ago

AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference

AnaptysBio price target raised to $50 from $36 at Truist

2026-03-09T11:22:33.000Z - 4 months ago

AnaptysBio price target raised to $50 from $36 at Truist

GSK

AnaptysBio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 11:50 AM EST - 4 months ago

AnaptysBio Transcript: TD Cowen 46th Annual Health Care Conference

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Mar 3, 2026, 4:15 PM EST - 4 months ago

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

AnaptysBio Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 4 months ago

AnaptysBio Annual report: Q4 2025

AnaptysBio Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 4 months ago

AnaptysBio Earnings release: Q4 2025

AnaptysBio Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 4 months ago

AnaptysBio Slides: Corporate presentation

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Feb 25, 2026, 7:18 AM EST - 4 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

AnaptysBio Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 12, 2026, 1:00 PM EST - 4 months ago

AnaptysBio Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

AnaptysBio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 3:00 PM EST - 4 months ago

AnaptysBio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Anaptys Announces Participation at Upcoming Investor Conferences

Feb 5, 2026, 4:15 PM EST - 5 months ago

Anaptys Announces Participation at Upcoming Investor Conferences

AnaptysBio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 6 months ago

AnaptysBio Transcript: 44th Annual J.P. Morgan Healthcare Conference

AnaptysBio Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 6 months ago

AnaptysBio Slides: Corporate presentation

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Jan 8, 2026, 7:09 PM EST - 6 months ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

GSK

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Jan 8, 2026, 6:00 PM EST - 6 months ago

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:15 PM EST - 6 months ago

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Dec 15, 2025, 7:00 AM EST - 7 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

AnaptysBio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:55 AM EST - 7 months ago

AnaptysBio Transcript: Evercore ISI 8th Annual HealthCONx Conference

AnaptysBio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:30 PM EST - 7 months ago

AnaptysBio Transcript: Piper Sandler 37th Annual Healthcare Conference

Anaptys Announces Participation in December Investor Conferences

Nov 25, 2025, 4:15 PM EST - 7 months ago

Anaptys Announces Participation in December Investor Conferences

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Nov 21, 2025, 8:52 AM EST - 7 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

Nov 21, 2025, 6:14 AM EST - 7 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 4:00 AM EST - 7 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

Nov 21, 2025, 3:50 AM EST - 7 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

AnaptysBio Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:00 AM EST - 8 months ago

AnaptysBio Transcript: Jefferies London Healthcare Conference 2025

AnaptysBio Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 1:20 PM EST - 8 months ago

AnaptysBio Transcript: Stifel 2025 Healthcare Conference

AnaptysBio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:30 AM EST - 8 months ago

AnaptysBio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

AnaptysBio Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 8:00 AM EST - 8 months ago

AnaptysBio Transcript: TD Cowen Immunology and Inflammation Summit

AnaptysBio Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 8 months ago

AnaptysBio Slides: Corporate Presentation

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 10, 2025, 9:00 AM EST - 8 months ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 8 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Nov 4, 2025, 4:15 PM EST - 8 months ago

Anaptys Announces Participation in November Investor Conferences

AnaptysBio Quarterly report: Q3 2025

Nov 4, 2025, 3:00 PM EST - 8 months ago

AnaptysBio Quarterly report: Q3 2025

AnaptysBio Earnings release: Q3 2025

Nov 4, 2025, 3:00 PM EST - 8 months ago

AnaptysBio Earnings release: Q3 2025

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 29, 2025, 9:15 AM EDT - 8 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

AnaptysBio Transcript: Status Update

Oct 14, 2025, 4:30 PM EDT - 9 months ago

AnaptysBio Transcript: Status Update

AnaptysBio Slides: Status Update

Oct 14, 2025, 4:30 PM EDT - 9 months ago

AnaptysBio Slides: Status Update

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Oct 13, 2025, 9:15 AM EDT - 9 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio Transcript: Investor Update

Sep 29, 2025, 4:30 PM EDT - 9 months ago

AnaptysBio Transcript: Investor Update

AnaptysBio Press release: Investor Update

Sep 29, 2025, 4:30 PM EDT - 9 months ago

AnaptysBio Press release: Investor Update

AnaptysBio Slides: Investor Update

Sep 29, 2025, 4:30 PM EDT - 9 months ago

AnaptysBio Slides: Investor Update

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 9 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Sep 29, 2025, 4:05 PM EDT - 9 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

AnaptysBio Slides: Corporate Presentation

Sep 29, 2025, 7:00 AM EDT - 9 months ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 12:00 PM EDT - 10 months ago

AnaptysBio Transcript: Stifel Virtual Immunology and Inflammation Forum

AnaptysBio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 11:00 AM EDT - 10 months ago

AnaptysBio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AnaptysBio Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

AnaptysBio Transcript: Cantor Global Healthcare Conference 2025

Anaptys Announces Participation in September Investor Conferences

Aug 27, 2025, 4:15 PM EDT - 10 months ago

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:15 PM EDT - 11 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

AnaptysBio Quarterly report: Q2 2025

AnaptysBio Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

AnaptysBio Earnings release: Q2 2025

AnaptysBio Slides: Corporate Presentation

Jun 16, 2025, 7:00 AM EDT - 1 year ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 8:40 AM EDT - 1 year ago

AnaptysBio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AnaptysBio Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 8:45 AM EDT - 1 year ago

AnaptysBio Transcript: Jefferies Global Healthcare Conference 2025

AnaptysBio Slides: FY 2025

Jun 5, 2025, 8:45 AM EDT - 1 year ago

AnaptysBio Slides: FY 2025

AnaptysBio Transcript: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Transcript: Status Update

AnaptysBio Press release: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Press release: Status Update

AnaptysBio Slides: Status Update

Jun 3, 2025, 4:15 PM EDT - 1 year ago

AnaptysBio Slides: Status Update

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 27, 2025, 4:15 PM EDT - 1 year ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

AnaptysBio Quarterly report: Q1 2025

AnaptysBio Earnings release: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

AnaptysBio Earnings release: Q1 2025

AnaptysBio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AnaptysBio Proxy statement: Proxy Filing

AnaptysBio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AnaptysBio Proxy statement: Proxy Filing

Anaptys Announces Stock Repurchase Plan

Mar 24, 2025, 9:15 AM EDT - 1 year ago

Anaptys Announces Stock Repurchase Plan

AnaptysBio Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

AnaptysBio Transcript: Barclays 27th Annual Global Healthcare Conference

AnaptysBio Slides: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

AnaptysBio Slides: Barclays 27th Annual Global Healthcare Conference

AnaptysBio Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

AnaptysBio Transcript: Leerink’s Global Healthcare Conference 2025

AnaptysBio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 1:10 PM EST - 1 year ago

AnaptysBio Transcript: TD Cowen 45th Annual Healthcare Conference

Anaptys Announces Participation in March Investor Conferences

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AnaptysBio Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

AnaptysBio Annual report: Q4 2024

AnaptysBio Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

AnaptysBio Earnings release: Q4 2024

AnaptysBio Transcript: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Transcript: Study Update

AnaptysBio Press release: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Press release: Study Update

AnaptysBio Slides: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

AnaptysBio Slides: Study Update

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 11, 2025, 5:30 PM EST - 1 year ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

AnaptysBio Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:00 PM EST - 1 year ago

AnaptysBio Transcript: Guggenheim SMID Cap Biotech Conference

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 4:15 PM EST - 1 year ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Feb 3, 2025, 7:30 AM EST - 1 year ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

AnaptysBio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

AnaptysBio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AnaptysBio Slides: FY 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

AnaptysBio Slides: FY 2025

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

AnaptysBio Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 1:45 PM EST - 1 year ago

AnaptysBio Transcript: 7th Annual Evercore ISI HealthCONx Conference

AnaptysBio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AnaptysBio Transcript: Piper Sandler 36th Annual Healthcare Conference

AnaptysBio Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 1:50 PM EST - 1 year ago

AnaptysBio Transcript: Stifel 2024 Healthcare Conference

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q3 2024

Nov 5, 2024, 3:00 PM EST - 1 year ago

AnaptysBio Quarterly report: Q3 2024

AnaptysBio Earnings release: Q3 2024

Nov 5, 2024, 3:00 PM EST - 1 year ago

AnaptysBio Earnings release: Q3 2024

AnaptysBio Registration statement: Registration Filing

Nov 5, 2024, 7:00 AM EST - 1 year ago

AnaptysBio Registration statement: Registration Filing

AnaptysBio Slides: Corporate Presentation

Nov 4, 2024, 6:00 PM EST - 1 year ago

AnaptysBio Slides: Corporate Presentation

AnaptysBio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 9:45 AM EDT - 1 year ago

AnaptysBio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

AnaptysBio Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 10:15 AM EDT - 1 year ago

AnaptysBio Transcript: 2024 Wells Fargo Healthcare Conference

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 14, 2024, 5:00 AM EDT - 2 years ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 4:15 PM EDT - 2 years ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

AnaptysBio Quarterly report: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

AnaptysBio Quarterly report: Q2 2024

AnaptysBio Earnings release: Q2 2024

Aug 5, 2024, 4:00 PM EDT - 2 years ago

AnaptysBio Earnings release: Q2 2024

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:15 PM EDT - 2 years ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:10 PM EDT - 2 years ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

thecontracap
thecontracap Jun. 18 at 8:29 PM
$ANAB anyone know the litigation with gsk in detail? Seems to me like $ANAB either gets a big royalty bump or they get acquired. Would like to compare notes in anyone involved.
1 · Reply
StockBraker
StockBraker Jun. 11 at 5:16 PM
$ANAB Should have sold more at $72. 😩
0 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 10 at 2:22 PM
$SPRO only to (1) avoid milestones/royalties to improve gross margin/operating earnings % and (2) avoid a future license dispute like $GSK and $ANAB and optimize GSK's $9 million equity investment in SPRO into something more useful via rolling into a reverse merge target.
0 · Reply
DARKP00L
DARKP00L Jun. 10 at 11:38 AM
$ANAB 06:20 on Jun. 10 2026 HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95 #tradeideas
0 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 9 at 4:21 PM
maybe the miscalculation re $SPRO all along is $GSK doesn't mind cutting milestone/royalty checks. Seems odd to me if you can extinguish those payments on what is supposedly a potential blockbuster. I thought GSK would want full control of all its blockbusters and out-license non-blockbusters like it did with Lynavoy in March 2026. GSK has problem with $ANAB and the jemperli license ...
1 · Reply
Reanimated666
Reanimated666 Jun. 3 at 11:20 AM
$ANAB After the spinoff the stock has dumped
1 · Reply
StockBraker
StockBraker May. 22 at 1:33 AM
$ANAB My friend would appreciate this part of this article. https://www.zacks.com/stock/news/2923367/wall-street-analysts-see-a-3875-upside-in-anaptysbio-anab-can-the-stock-really-move-this-high?cid=CS-STOCKTWITS-HL-tale_of_the_tape|consensus_price_target-2923367&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2923367#:~:text=Here%27s%20What%20You%20Should%20Know%20About%20Analysts%27%20Price%20Targets
1 · Reply
inelegantinvest
inelegantinvest May. 21 at 1:59 PM
$ANAB completed the First Tracks Biotherapeutics spinoff. Now ANAB is the royalty/cash story, while $TRAX.X is the pipeline company. The split makes the investment question cleaner — but not automatically cheaper. We looked at both sides: https://www.stockspinoffs.com/2026/05/21/anaptysbio-first-tracks-spinoff-completed/
0 · Reply
Grallen
Grallen May. 19 at 8:31 PM
$ANAB https://www.instagram.com/reel/DYfXmRshgf-/?igsh=MWNlaDQxZmwxZHUycQ==
0 · Reply
Grallen
Grallen May. 8 at 8:50 PM
$ANAB https://www.instagram.com/p/DX9EIjmMhfQ/?igsh=MTRweGgyNnJnOTU1MQ==
0 · Reply
StockBraker
StockBraker May. 4 at 9:45 PM
$ANAB 🤣🤣
0 · Reply
StockBraker
StockBraker May. 4 at 2:05 PM
$ANAB May 15 exp, $75 strike covered call just executed at $3.50 per contract.
0 · Reply
Quantumup
Quantumup May. 4 at 10:35 AM
Piper Sandler🏁 $TRAX.X and said: We are initiating coverage on First Tracks Biotherapeutics, Inc. (TRAX) with an OW rating and $54 PT given its differentiated pipeline across ANB033 (CD122 antagonist), rosnilimab (pathogenic T-cell depleter), and ANB101 (BDCA2 modulator). $ANAB ENTO FBRX TAK SNY TEVA AZN BMY $EPRX PHAT ABBV GILD REGN PFE LLY Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2051248806482612476?s=20
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 2:24 PM
$ANAB Share Price: $63.20 Contract Selected: Nov 20, 2026 $65 Calls Buy Zone: $10.62 – $13.12 Target Zone: $19.33 – $23.63 Potential Upside: 72% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockBraker
StockBraker Apr. 30 at 1:37 PM
$ANAB 11 ranked analysts covering with a current COYPT of $78.45. Leerink is the most recent with $85. Most recent 5 shown below.
0 · Reply
MikeyMcDermott
MikeyMcDermott Apr. 28 at 7:57 PM
from $GSK Q4 report 2 major product approvals expected -- bepirovirsen PDUFA date set today for October 26, 2026 --- partner $IONS $12B market cap too big to acquire tebipenem is next June 18.. with $SPRO $160 million market cap out of the readouts -- jemperli (contract dispute with $ANAB) one would think GSK would want to fully own blockbusters
0 · Reply
MikeyMcDermott
MikeyMcDermott Apr. 28 at 4:56 PM
looks like $GSK puts $SPRO assets inside same Tesaro subsidiary as $ANAB GSK also buys stuff from this list -- Bellus Health, Affinax, etc Book a win and have a positive partner story to tell on earnings call -- 100% ownership of blockbuster tebipenem offsetting the problems with ANAB contract/license dispute.
1 · Reply
MikeyMcDermott
MikeyMcDermott Apr. 28 at 4:19 PM
$SPRO also you have to wonder if $GSK wants to wrap up a SPRO deal to avoid a partner dispute like $ANAB over one of its identified blockbuster drugs that makes up big portion of 2031 guidance. ** acquiring SPRO would also be accretive to operating margins by avoiding 200mln/yr in royalties.
1 · Reply
StockBraker
StockBraker Apr. 28 at 2:26 PM
$ANAB $TRAXV Combined price is now $87+ BTW @Stocktwits - The symbol for First Tracks is officially TRAX now.
0 · Reply
StockBraker
StockBraker Apr. 28 at 2:24 PM
$TRAXV $ANAB
0 · Reply
Quantumup
Quantumup Apr. 28 at 11:36 AM
H.C. Wainwright🏁 $TRAX.X Buy; $30., and said: A biopharma spin-out equipped with a pipeline of high potency immunomodulators. $ANAB $FBRX NVS EPRX BMY ABBV REGN AMGN BIIB ARGX KNSA Here's what else H.C. Wainwright had to say in its initiation report: https://x.com/Quantumup1/status/2049089378358645033?s=20
0 · Reply
StockBraker
StockBraker Apr. 27 at 6:07 PM
$ANAB AnaptysBio Inc. (ANAB) shares are surging on April 27, 2026, primarily due to a major favorable ruling from the Delaware Chancery Court in its dispute with GSK’s Tesaro, which dismissed a lawsuit regarding royalty payments, and the positive market reception to its restructuring into a royalty management company following the spinoff of First Tracks Biotherapeutics.
0 · Reply